DarioHealth Corp.
DRIONasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $22.4M | $27.0M | $20.4M | $27.7M | $20.5M | $7.6M |
| Operating income | −$36.7M | −$57.7M | −$56.2M | −$56.8M | −$76.5M | −$29.9M |
| Net income | −$41.7M | −$42.7M | −$59.4M | −$62.2M | −$76.8M | −$29.4M |
| Total assets | $110.1M | $118.9M | $96.4M | $119.2M | $100.8M | $35.4M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $67.9M | $72.0M | $58.1M | $80.0M | $85.5M | $28.2M |
| EPS (diluted) | $10.12 | $0.61 | $1.93 | $2.54 | $4.07 | $4.01 |
| Shares out. | 41.6M | 29.4M | 25.9M | 21.8M | 15.3M | 3.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −163.9%
- Net margin
- −186.6%
- Return on equity
- −61.4%
- Return on assets
- −37.9%
- Return on capital (ROCE)
- −36.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.63
- Revenue growth (YoY)
- −17.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −14.3%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nelson Steven CharlesOfficer — President and CCO | Sep 11, 2025 | Grant | 30,000 | $0.00 |
| Stern Adam KDirector | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Leisure Lawrence B.Director | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Shaked YoavDirector | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Raphael ErezOfficer — Chief Executive Officer | Sep 11, 2025 | Grant | 60,000 | $0.00 |
| Franco-Yehuda ChenOfficer — Chief Financial Officer | Sep 11, 2025 | Grant | 5,000 | $0.00 |
| Mcgrath Dennis MDirector | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Karah HilaDirector | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Matheis DennisDirector | Sep 11, 2025 | Grant | 20,000 | $0.00 |
| Nelson Steven CharlesOfficer — President and CCO | Aug 27, 2025 | Buy | 40,000 | $0.53 |
| Franco-Yehuda ChenOfficer — Chief Financial Officer | May 15, 2025 | Grant | 500,000 | $0.00 |
| Kaplan Jon H.Director | Feb 24, 2025 | Grant | 30,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 72,783 | 10.6 | +8.7% |
| Apr 30, 2026 | 66,947 | 5.1 | -3.2% |
| Apr 15, 2026 | 69,155 | 2.9 | +4.8% |
| Mar 31, 2026 | 66,009 | 4.6 | +47.3% |
| Mar 13, 2026 | 44,799 | 5.0 | -11.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventApr 13, 2026
- Entered a material agreementMar 30, 2026
- Amended charter or bylawsFeb 2, 2026
- Shareholder voteJan 29, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleNov 10, 2025
- Entered a material agreement · Unregistered equity sale · Amended charter or bylaws · Other material eventSep 25, 2025
- Modified shareholder rights · Amended charter or bylawsSep 19, 2025
- Other material eventSep 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 13, 2026
- SDMay 7, 2026
- 3OWNERSHIP DOCUMENTApr 13, 2026
- 8-KFORM 8-KApr 13, 2026
- 424B5Mar 30, 2026
- 8-KFORM 8-KMar 30, 2026
- EFFECTMar 27, 2026
- CORRESPMar 25, 2026
- UPLOADMar 25, 2026
- S-8FORM S-8Mar 19, 2026
- S-3FORM S-3Mar 19, 2026
- 10-KMar 19, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 8-KFORM 8-KFeb 2, 2026
- 8-KFORM 8-KJan 29, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.